ZolpiMist USA seems to be bullish, page-108

SUD-001 | Oral spray for migraine 
SUD-001 is first oral spray of sumatriptan (GSK’s Imitrex® tablet) for rapid relief of migraine headache
 Migraine market is approx $3.2 billion. Sumatriptan has 50% market share  Phase II study showed quicker onset of action and less drug needed to achieve pain relief vs. Imitrex tablet
 Primary Market Research suggests prescribers & payers see important role for SUD-001 in patients with nausea, GI problems or sudden onset headaches
 Successful meeting with FDA in 2015 regarding pivotal development plan - FDA accepted novel pharmacokinetic trial design, thus avoiding the need for costly efficacy studies prior to approval